171 related articles for article (PubMed ID: 24051549)
1. Melanoma-associated retinopathy treated with ipilimumab therapy.
Audemard A; de Raucourt S; Miocque S; Comoz F; Giraud JM; Dreno B; Bienvenu B; Rogerie MJ; Dompmartin A
Dermatology; 2013; 227(2):146-9. PubMed ID: 24051549
[TBL] [Abstract][Full Text] [Related]
2. Outcomes Associated With Sustained-Release Intraocular Fluocinolone Implants in a Case of Melanoma-Associated Retinopathy Treated Without Systemic Immunosuppression.
Karatsai E; Robson AG; Taylor SRJ
JAMA Ophthalmol; 2019 May; 137(5):564-567. PubMed ID: 30896772
[TBL] [Abstract][Full Text] [Related]
3. Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone.
Poujade L; Samaran Q; Mura F; Guillot B; Meunier I; Du-Thanh A
Doc Ophthalmol; 2021 Apr; 142(2):257-263. PubMed ID: 32975694
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis of occult melanoma using transient receptor potential melastatin 1 (TRPM1) autoantibody testing: a novel approach.
Dalal MD; Morgans CW; Duvoisin RM; Gamboa EA; Jeffrey BG; Garg SJ; Chan CC; Sen HN
Ophthalmology; 2013 Dec; 120(12):2560-2564. PubMed ID: 24053997
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
6. Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy.
Pintova S; Sidhu H; Friedlander PA; Holcombe RF
Melanoma Res; 2013 Dec; 23(6):498-501. PubMed ID: 24113862
[TBL] [Abstract][Full Text] [Related]
7. Melanoma-associated retinopathy.
Elsheikh S; Gurney SP; Burdon MA
Clin Exp Dermatol; 2020 Mar; 45(2):147-152. PubMed ID: 31742740
[TBL] [Abstract][Full Text] [Related]
8. A case of melanoma-associated retinopathy with autoantibodies against TRPM1.
Kim MS; Hong HK; Ko YJ; Park KH; Ueno S; Okado S; Woo SJ; Joo K
Doc Ophthalmol; 2020 Dec; 141(3):313-318. PubMed ID: 32472235
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-Associated Retinopathy.
Crews J; Agarwal A; Jack L; Xu D; Do DV; Nguyen QD
Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):658-60. PubMed ID: 26114847
[TBL] [Abstract][Full Text] [Related]
10. CHOROIDAL NEOVASCULARIZATION AND CHORIORETINAL ATROPHY IN A PATIENT WITH MELANOMA-ASSOCIATED RETINOPATHY AFTER IPILIMUMAB/NIVOLUMAB COMBINATION THERAPY.
Elwood KF; Pulido JS; Ghafoori SD; Harper CA; Wong RW
Retin Cases Brief Rep; 2021 Sep; 15(5):514-518. PubMed ID: 31246886
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
[TBL] [Abstract][Full Text] [Related]
12. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
[TBL] [Abstract][Full Text] [Related]
13. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
[TBL] [Abstract][Full Text] [Related]
14. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies to transient receptor potential cation channel, subfamily M, member 1 in a Japanese patient with melanoma-associated retinopathy.
Morita Y; Kimura K; Fujitsu Y; Enomoto A; Ueno S; Kondo M; Sonoda KH
Jpn J Ophthalmol; 2014 Mar; 58(2):166-71. PubMed ID: 24468869
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab-induced acute severe colitis treated by infliximab.
Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
[TBL] [Abstract][Full Text] [Related]
17. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature.
Aronow ME; Adamus G; Abu-Asab M; Wang Y; Chan CC; Zakov ZN; Singh AD
Surv Ophthalmol; 2012 Nov; 57(6):558-64. PubMed ID: 22784677
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab: a guide to its use in advanced melanoma.
Lyseng-Williamson KA; Sanford M
Am J Clin Dermatol; 2012 Oct; 13(5):349-54. PubMed ID: 22849352
[TBL] [Abstract][Full Text] [Related]
19. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.
Chan PY; Hall P; Hay G; Cohen VML; Szlosarek PW
Pigment Cell Melanoma Res; 2017 Jan; 30(6):558-562. PubMed ID: 28640512
[TBL] [Abstract][Full Text] [Related]
20. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
